Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 35Prostate Cancer Metastatic 3Neoplasm Metastasis 3Prostate CA 2Metastatic Hormone-sensitive Prostate Cancer (mHSPC) 2Triple Negative Breast Neoplasms 1Prostatic Neoplasms, Castration-Resistant 1Prostatic Diseases 1Oligometastatic Prostate Cancer 1Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) 1Metastatic Castration-resistant Prostate Cancer 1Intraprostatic Prostate Cancer 1Genital Diseases, Male 1Breast Neoplasms 1Adenocarcinoma 1

Interventions

darolutamide 3Pluvicto 3Docetaxel 3testosterone 17 beta-cypionate 2sipuleucel-T 1lactitol 1fludarabine phosphate 1fludarabine 1enzalutamide 1ebastine 1cabozantinib 1cabazitaxel 1Standard of Care 1Prednisone 1Prednisolone 1PSMA-617 1Gonadotropin-Releasing Hormone 1Cyclophosphamide 1Bortezomib 1Blood Specimen Collection 1Androgen Antagonists 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Metastatic Castration-resistant Prostate Cancer × Androgen Antagonists × Clear all
NCT07476001 2026-05-15

Phase 2a Study of High-Dose Testosterone Followed by Radioligand Therapy in mCRPC

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Recruiting
12 enrolled
Genitourinary

Metastatic Castration-resistant Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡